Last $19.22 USD
Change Today +3.15 / 19.60%
Volume 1.4M
AMED On Other Exchanges
As of 1:38 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

amedisys inc (AMED) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/30/14 - $19.24
52 Week Low
07/30/13 - $11.36
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AMEDISYS INC (AMED)

amedisys inc (AMED) Related Businessweek News

View More BusinessWeek News

amedisys inc (AMED) Details

Amedisys Inc. provides home health and hospice services including practical nursing services and physical and occupational therapy. The company’s services also comprise speech pathology, social work to help families address acute and chronic illnesses, home health aide services, and private duty services. Hospice services use a team made up of a physician, patient care manager, registered nurses, certified home health aides, social workers, a chaplain, a homemaker, and volunteers. As of Apr. 4, 2007, the company operated 261 Medicare-certified home health agencies and 14 Medicare-certified hospice agencies in 19 states. Amedisys was founded in 1982 and is headquartered in Baton Rouge, La.

14,300 Employees
Last Reported Date: 03/12/14
Founded in 1982

amedisys inc (AMED) Top Compensated Officers

Interim Chief Executive Officer, President an...
Total Annual Compensation: $514.2K
Chief Medical Officer
Total Annual Compensation: $308.5K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $277.3K
Chief Compliance Officer
Total Annual Compensation: $270.6K
Compensation as of Fiscal Year 2013.

amedisys inc (AMED) Key Developments

Amedisys Inc. Announces New $70 Million Second Lien Credit Facility and Amendment to Senior Secured Credit Facility

Amedisys Inc. announced that it entered into a new $70 million six-year second lien term loan facility. In connection with the new second lien facility, the company's existing senior secured credit facility was amended and downsized to $159 million, consisting of an existing term loan with a balance of $39 million and a $120 million revolving credit facility. The maturity of the senior secured facility will remain unchanged. Proceeds from the new term loan were used to pay down outstanding revolver balances. The interest rate of the second lien term loan is priced at LIBOR plus 7.5% with a 1.0% LIBOR floor.

Amedisys Inc. to Report Q2, 2014 Results on Jul 30, 2014

Amedisys Inc. announced that they will report Q2, 2014 results on Jul 30, 2014

Amedisys Announces Completion of SEC Investigation

Amedisys Inc. announced that it has been advised by the staff of the Securities and Exchange Commission (SEC) that the investigation by the SEC related to the company's operations and participation in the Medicare program has been completed and that the staff does not intend to recommend any enforcement action by the SEC. The company had previously reported the existence of this investigation in June 2010.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMED:US $19.22 USD +3.15

AMED Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almost Family Inc $23.31 USD +0.14
BioScrip Inc $7.65 USD +0.199
Chemed Corp $102.83 USD +0.04
Gentiva Health Services Inc $18.17 USD +0.06
LHC Group Inc $21.78 USD +0.18
View Industry Companies

Industry Analysis


Industry Average

Valuation AMED Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.4x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMEDISYS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at